☰

Christopher Pennell - Publications

Affiliations: 
Microbiology, Immunology and Cancer Biology University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Pennell CA, Campbell H, Storlie MD, Bolivar-Wagers S, Osborn MJ, Refaeli Y, Jensen M, Viaud S, Young TS, Blazar BR. Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19 malignancy. Journal For Immunotherapy of Cancer. 10. PMID 36521930 DOI: 10.1136/jitc-2022-005934  0.476
2022 Bolivar-Wagers S, Loschi ML, Jin S, Thangavelu G, Larson JH, McDonald-Hyman CS, Aguilar EA, Saha A, Koehn BH, Hefazi M, Osborn MJ, Jensen MC, Wagner JE, Pennell CA, Blazar BR. Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses. Jci Insight. PMID 35917188 DOI: 10.1172/jci.insight.160674  0.314
2019 Rosato PC, Wijeyesinghe S, Stolley JM, Nelson CE, Davis RL, Manlove LS, Pennell CA, Blazar BR, Chen CC, Geller MA, Vezys V, Masopust D. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nature Communications. 10: 567. PMID 30718505 DOI: 10.1038/S41467-019-08534-1  0.394
2019 Olin MR, Ampudia-Mesias E, Pennell CA, Sarver A, Chen CC, Moertel CL, Hunt MA, Pluhar GE. Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma. Cancers. 11. PMID 30682795 DOI: 10.3390/Cancers11020137  0.467
2019 Moertel C, Pluhar GE, Ampudia-Mesias E, Xiong Z, Pennell CA, Rathe SK, Largaespada DA, Olin MR. IMMU-23. TARGETING THE CD200 CHECKPOINT TO ENHANCE IMMUNOTHERAPY FOR CNS TUMORS Neuro-Oncology. 21: ii97-ii98. DOI: 10.1093/Neuonc/Noz036.142  0.352
2018 Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, et al. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29735365 DOI: 10.1016/J.Ymthe.2018.04.006  0.472
2018 Olin M, Ampudia-Mesias E, Pennell CA, Xiong Z, Rathe SK, Largaespada DA, Moertel CL, Pluhar GE. CADD-14. TARGETING THE CD200 CHECKPOINT FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 20: vi278-vi279. DOI: 10.1093/Neuonc/Noy148.1159  0.332
2015 Pluhar GE, Pennell CA, Olin MR. CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity. Critical Reviews in Immunology. 35: 153-72. PMID 26351148 DOI: 10.1615/Critrevimmunol.2015013607  0.451
2015 Pluhar GE, Pennell CA, Olin MR. CD8<sup>+</sup> T cell–independent immune-mediated mechanisms of anti-tumor activity Critical Reviews in Immunology. 35: 153-172. DOI: 10.1615/CritRevImmunol.2015013607  0.449
2014 Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. Journal For Immunotherapy of Cancer. 2: 46. PMID 25598973 DOI: 10.1186/S40425-014-0046-9  0.416
2013 Dietz WM, Skinner NE, Hamilton SE, Jund MD, Heitfeld SM, Litterman AJ, Hwu P, Chen ZY, Salazar AM, Ohlfest JR, Blazar BR, Pennell CA, Osborn MJ. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1526-35. PMID 23689601 DOI: 10.1038/Mt.2013.85  0.699
2013 Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, Salazar AM, Olin MR. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. Journal of Immunology (Baltimore, Md. : 1950). 190: 613-20. PMID 23248259 DOI: 10.4049/Jimmunol.1201557  0.348
2006 Erickson HA, Jund MD, Pennell CA. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition. Protein Engineering, Design & Selection : Peds. 19: 37-45. PMID 16243897 DOI: 10.1093/Protein/Gzi073  0.745
2002 Harmala LA, Ingulli EG, Curtsinger JM, Lucido MM, Schmidt CS, Weigel BJ, Blazar BR, Mescher MF, Pennell CA. The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo. Journal of Immunology (Baltimore, Md. : 1950). 169: 5622-9. PMID 12421941 DOI: 10.4049/Jimmunol.169.10.5622  0.463
2002 Pennell CA, Erickson HA. Designing immunotoxins for cancer therapy. Immunologic Research. 25: 177-91. PMID 11999171 DOI: 10.1385/Ir:25:2:177  0.702
2001 Erickson HA, Reinhardt RL, Hermanson JB, Panoskaltsis-Mortari A, Pennell CA. Visualization of immunotoxin-mediated tumor cell death in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 890s-894s. PMID 11300488  0.721
1997 Pauza ME, Doumbia SO, Pennell CA. Construction and Characterization of Human CD7-Specific Single-Chain Fv Immunotoxins Journal of Immunology. 158: 3259-3269. PMID 9120282  0.496
1996 Vallera DA, Burns LJ, Frankel AE, Sicheneder AR, Gunther R, Gajl-Peczalska K, Pennell CA, Kersey JH. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. Journal of Immunological Methods. 197: 69-83. PMID 8890895 DOI: 10.1016/0022-1759(96)00127-5  0.469
1996 Vallera DA, Panoskaltsis-Mortari A, Jost C, Ramakrishnan S, Eide CR, Kreitman RJ, Nicholls PJ, Pennell C, Blazar BR. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single- chain Fv fusion immunotoxin specifically targeting the CD3ε moiety of the T- cell receptor Blood. 88: 2342-2353. PMID 8822957  0.408
1995 Bejcek BE, Wang D, Berven E, Pennell CA, Peiper SC, Poppema S, Uckun FM, Kersey JH. Development and Characterization of Three Recombinant Single Chain Antibody Fragments (scFvs) Directed against the CD19 Antigen Cancer Research. 55: 2346-2351. PMID 7538901  0.356
Show low-probability matches.